Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes

Diabetes

Volumn 45, Issue 10, 1996, Pages 1427-1430

  Bjork E ^a   Berne, C ^a   Kampe O ^a   Wibell, L ^a   Oskarsson, P ^b   Karlsson, F Anders ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZOXIDE;

ADULT; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG THERAPY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; MALE; PRIORITY JOURNAL;

EID: 0029784458     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.45.10.1427     Document Type: Article

References (23)

1. Leahy JL, Bonner-Weir S, Weir GC: Minimal chronic hyperglycemia is a critical determinant of impaired insulin secretion after an incomplete pancreatectomy. J Clin Invest 81:1407-1414, 1988
2. 1 islet cell autoantigen expression. Diabetes 38:1326-1328, 1989
3. 65 in human pancreatic islets. J Clin Endocrinol Metab 75:1574-1576, 1992
4. Hagopian WA, Karlsen AE, Petersen JS, Teague J, Gervassi A, Jiang J, Fujimoto W, Lernmark A: Regulation of glutamic acid decarboxylase diabetes autoantigen expression in highly purified isolated islets from Macaca nemestrina. Endocrinology 132:2674-2681, 1993
5. McCulloch DK, Barmeier H, Neifmg JL, Palmer JP: Metabolic state of the pancreas affects end-point titre in the islet cell antibody assay. Diabetologia 34:622-625, 1991
6. Björk E, Kämpe O, Gravé J, Hallberg A, Norheim I, Karlsson FA: Modulation of beta-cell activity and its influence on islet cell antibody (ICA) and islet cell surface antibody (ICSA) reactivity. Autoimmunity 16:181-188, 1993
7. Björk E, Kämpe O, Andersson A, Karlsson FA: Expression of the 64 kDa/GAD rat islet cell autoantigen is influenced by the rate of insulin secretion. Diabetologia 32:490-493, 1992
8. Greenwood RH, Mahler RF, Hales ON: Improvement in insulin secretion in diabetes after diazoxide. Lanrcet 1:444-447, 1976
9. Antoine MH, Pirotte B, Hermann M, de Tullio P, Delarge J, Herchuelz A, Lebrun P: Cationic and secretory effects of BPDZ 44 and diazoxide in rat pancreatic islets. Experientia 50:830-832, 1994
10. Grubin CE, Daniels T, Toivola B, Landin-Olsson M, Hagopian WA, Li L, Karlsen AE, Boel E, Michelsen B, Lernmark Å: A novel radioliganri binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia 37:344-350, 1994
11. Sjöberg S, Gunnarsson R, Gjötterberg M, Lefvert AK, Persson A, Ostman J: Residual insulin production, glycemic control and prevalence of microvascular lesions and polyneuropathy in long-term type 1 (insulin-dependent) diabetes mellitus. Diabetologia 30:208-213, 1987
12. Nakanishi K, Kobayashi T, Miyashita H, Ohkubo M, Sugimoto T, Murase T, Kosaka K, Inouye K, Kono K: Relationships among islet cell antibodies, residual β-cell function, and metabolic control in patients with insulin-dependent diabetes mellitus of long duration: use of sensitive C-peptide radioimmunoassay. Metabolism 39:925-930, 1990
13. Nakanishi K, Kobayashi T, Inoko H, Tsuji K, Murase T, Kosaka K: Residual β-cell function and HLA-A24 in IDDM: markers of glycemic control and subsequent development of diabetic retinopathy. Diabetes 44:1334-1339, 1995
14. The DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
15. Goode PN, Farndon JR, Anderson J, Johnston ID, Morte JA: Diazoxide in the management of patients with insulinoma. World J Surg 10:586-592, 1986
16. Grant DB, Dunger DB, Burns EC: Long-term treatment with diazoxide in childhood hyperinsulinism. Acta Endocrinol 113 (Suppl. 279):340-345, 1986
17. Sturgess NC, Kozlowsto RZ, Carrington CA, Hales CN, Ashford MLJ: Effects of sulphonylureas and diazoxide on insulin secretion and nucleotide-sensitive channels in an insulin secreting cell line. Br J Pharmacol 95:83-94, 1988
18. Baron AD, Steinberg H, Bretchel G, Johnson A: Skeletal muscle blood flow independently modulates insulin-mediated glucose uptake. Am J Physiol 266:E248-E253, 1994
19. Jansson R, Karlsson FA, Dahlberg PA: Thyroxine, methimazole, and thyroid microsomal autoantibody titres in hypothyroid Hashimoto's thyroiditis. Br Med J 290:11-12, 1985
20. Chiovato L, Marcocci C, Mariotti S, Mori A, Pinchera A: L-thyroxine therapy induces a fall of thyroid microsomal and thyroglobulin antibodies in idiopathic myxedema and in hypothyroid, but not in euthyroid Hashimoto's disease. J Endocrinol Invest 9:299-305, 1986
21. Volpé R, Karlsson FA, Jansson R, Dahlberg PA: Evidence that thyrostatic drugs induce remission in Graves' disease by modulating thyroid cellular activity. Clin Endocrinol 25:453-462, 1986
22. Eizirik DL, Sandier S, Palmer JP: Repair of pancreatic β-cells: a relevant phenomenon in early IDDM? Diabetes 42:1383-1391, 1993
23. Keller RJ, Eisenbarth GS, Jackson RA: Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet 341:927-928, 1993